PharmaMar, one of Luye Pharma’s collaborative partners, has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review the New Drug Application (NDA)...
December 1, 2019, Luye Pharma Group has announced the acquisition of Shandong Boan Biological Technology Co. Ltd. (Boan), accelerating its global strategy in the field of biopharmaceuticals. After the...
As one of the nation’s largest private mental health providers, October 10 is a very important date for Healthe Care, annually. It marks World Mental Health Day, an international day for global ...
Fairfield, NJ (November 5, 2019)-Vela Diagnostics announced that it has received FDA authorization to market its in vitro diagnostic test for the detection of HIV-1 genomic drug resistance mutations (...
LY03004, Luye Pharma’s innovative, independently developed Extended-Release Microspheres for Injection has taken another step closer to going on the U.S. market. The company has announced that i...
Since its establishment in 1994, Luye Life Sciences has expanded from the shore of the Yellow Sea in Yantai to Singapore, the United States, Germany, Japan, and Australia...and its staff has grown fro...
In following with the Chinese government’s call to "Promote the modernization of traditional Chinese medicine (TCM) and promote TCM to the world", as well as the Chinese government&rsq...
On March 23, 2019, the Development Research Center of the State Council hosted the “Economic Summit of China Development Forum 2019” at the Diaoyutai State Guesthouse in Beijing. The theme of this y...
On April 26, Luye Pharma Group announced an agreement with Pharma Mar S.A (“PharmaMar”) to develop and commercialize a Phase III new innovative anti-cancer drug: Zepsyre® (Lurbinectedin).According t...
From August 28 to 31, the 17th National Congress of Psychiatry (CSP2019) of the Chinese Medical Association was held in Nanjing. The conference brought together experts and scholars from around the wo...
TOP